Ibere Pharmaceuticals (IBER) · Income Statement

Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.

FMP · IBER · as of 2026-06-09

Financial statements

Revenue · Gross Profit · Net Income

Breakdown	2021-12
Revenue
Revenue	$0.00B
Cost of Revenue	$0.00B
Gross Profit	($0.00B)
Gross Margin %(computed)	—
Operating Expenses
R&D Expenses	$0.00B
G&A Expenses	$0.00B
Total Operating Expenses	$0.00B
Operating Income	($0.00B)
Operating Margin %(computed)	—
Interest Income	$0.00B
Interest Expense	$0.00B
Income Before Tax	$0.00B
Income Tax Expense	$0.00B
Net Income	$0.00B
Net Margin %(computed)	—
Per Share & EBITDA
EPS (Basic)	$0.34
Wtd Avg Shares	0.01B
EBITDA	($0.00B)
EBITDA Margin %(computed)	—

Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B

SEC 10-K filings →SEC 10-Q filings →

Explore more Ibere Pharmaceuticals data

Revenue History

Quarterly & annual revenue trends

Earnings Reports

EPS beats, misses & upcoming dates

P/E Ratio

Historical price-to-earnings

Dividends

Dividend history & yield

Market Cap

Historical market cap & rank

Analyst Forecast

Consensus, price targets & estimates

About Ibere Pharmaceuticals (IBER) Income Statement

Ibere Pharmaceuticals (IBER) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2021, IBER reported revenue of $0.00B, gross profit of ($0.00B) (gross margin —), and net income of $0.00B — a net profit margin of —.

Frequently asked questions

IBER · 4 questions

Ibere Pharmaceuticals (IBER) reported revenue of $0.00B for 2021, down —% year-over-year.

IBER revenueIBER salesannual revenue YoYincome statement

· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09